Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis
NCT: NCT05694988 · COMPLETED
Brief Summary
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF). Due to the lack of etiological therapy, the treatment of acute pancreatitis is predominantly symptomatic. Severity and mortality are associated with early systemic inflammatory response syndrome (SIRS) and septic complications in the later stages of the disease. In connection with a pronounced inflammatory reaction ("cytokine storm") in the early phase of endogenous intoxication of acute pancreatitis, a promising therapeutic approach is the extracorporeal removal of cytokines. This prospective study intends to study the effect of hemoperfusion (Efferon CT) in combination with high-volume hemofiltration (HVHF) on the severity of symptoms of endogenous intoxication and indicators of organ dysfunction in acute pancreatitis.
Frequently Asked Questions
What is Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis?
Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis is a clinical trial registered under NCT05694988. Current status: COMPLETED.
What is the status of NCT05694988?
The current status of NCT05694988 (Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis) is: COMPLETED.
When did Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis start?
Combination of Cytokine Hemosorption and High-volume Hemofiltration in Acute Pancreatitis started on 2022-11-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.